Status:
RECRUITING
Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Lymphoma
Hodgkin Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
Lymphoma is a prevalent lymphoid malignancy globally and in Taiwan. Large B-cell lymphoma (LBCL) is the most common subtype of aggressive B-cell lymphoma. LBCL's aggressive nature manifests through ex...
Eligibility Criteria
Inclusion
- • Pathology proven lymphoma
- Age ≥ 18 years old
Exclusion
- none
Key Trial Info
Start Date :
August 9 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 31 2027
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06550427
Start Date
August 9 2024
End Date
July 31 2027
Last Update
June 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan